Type 2 & other diabetes

Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention

Cardiovasc DiabetolPublished Retrospective cohort study

Authors' conclusion

The study results indicate that elevated levels of plasma inactive SDF-1α might be a useful indicator of poor long-term outcomes in diabetic patients following PCI.

Study context

Population
Consecutive patients with diabetes mellitus (DM) who underwent first percutaneous coronary intervention (PCI) between 2008 and 2018, Juntendo University Hospital, Tokyo, Japan
Participants
849 patients
Exposure
Plasma inactive, total and active SDF-1α levels as predictors of outcomes
Outcome
All-cause death
Methodological detailssingle-centre, consecutive patients, analysis of a prospective registry database, Total and active SDF-1α measured by ELISA; inactive isoform calculated as total minus active
  • Single-centre
  • Consecutive patients
  • Analysis of a prospective registry database
  • Total and active SDF-1α measured by ELISA; inactive isoform calculated as total minus active

Main finding

As reported in the abstract

All-cause death per 1 higher log-transformed inactive SDF-1α

HR (multivariate Cox) per 1 higher log-transformed inactive SDF-1α

2.64

95% CI 1.28–5.34p = 0.008

Observational data: associations, not effects.

Secondary outcomes

3P-MACE (CV death, non-fatal MI, ischemic stroke) per 1 higher log-transformed inactive SDF-1α

HR (multivariate Cox) per 1 higher log-transformed inactive SDF-1α
2.51 (95% CI 1.12-5.46; p = 0.02)
Unadjusted Kaplan-Meier: increased risk of 3P-MACE with elevated inactive SDF-1α

Predictive performance (C-statistic), inactive vs total SDF-1α

All-cause death: inactive vs total SDF-1α
0.631 vs 0.554
3P-MACE: inactive vs total SDF-1α
0.623 vs 0.524

Original publication

Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention. Cardiovasc Diabetol. Published 30 March 2024. doi:10.1186/s12933-024-02197-z

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.